Product Reports Resources Pricing Login Book a demo

Euglena

Biotech & Life Sciences · Tokyo, Japan · Founded 2005 · IPO 2012

Microalgae-based food, cosmetics, and biofuel development

Valuation $416M
Revenue $400M
EBITDA $55M
Power Law Thoroughbred$100M+ revenue

Talent graph

Euglena's talent

Book a demo to see the people
Founders Hidden — book a demo/100 quality score
Key operators Hidden — book a demo quality score
Potential founders Hidden — book a demo likely future founders
Startup mafia Hidden — book a demo alumni-founded startups
Talent movements Hidden — book a demo in · Hidden — book a demo out past 12 months

Source: Dealroom Talent Intelligence.

Investors

4 investors on Euglena's cap table

Sourced from Dealroom's funding and investor records. Investor profile links are shown where available.

Seed 2 investors entered at this stage
SBI Investment
Inspire
Series B+ 2 investors entered at this stage
J-Startup
The University of Tokyo

Global footprint

Where Euglena has talent and traffic

Workforce by country
6 countries with
team presence
🇯🇵 Japan79.8%
🇲🇾 Malaysia10.2%
🇺🇸 United States2.8%
🏳️ Bhutan2.4%
🇰🇷 South Korea2.4%
Top 5 of 6 shown
Web traffic by country
140K monthly visits
across markets
🇯🇵 Japan92.4%
🇺🇸 United States4.1%
🏳️ Korea1.1%
🏳️ Republic of0.5%
🇨🇦 Canada0.4%
Top 5 markets shown

Patent intelligence

$9M patent portfolio · 74 active families

Estimated portfolio value
$9M
2.1% of market cap · 34.9× smaller than top peer Actelion Pharmaceuticals ($304M)
74 active patent families
Where Euglena innovates Active ingredientBULK ACTIVE INGREDIENTBiotechnologyCosmeticsCulture mediums

Where Euglena concentrates vs peers

Each axis is a top-10 topic across Euglena and its closest peers. #1 = 100, #10 = 10, absent = 0.

Compare against

Source: Dealroom Patent Intelligence · Patsnap. Request a demo for the full per-sub-category breakdown, individual records, and quality-score history.

Capital deployed

Euglena's 4 investments and acquisitions.

Every disclosed deal where Euglena appeared as a backer or acquirer, 2016–2022. Toggle between venture rounds, M&A, or both. The map below is grouped by the target company's sector — the colored pill on each chip is the round type.

Portfolio analysis

4 deals across Euglena's capital deployment.

Where the deals concentrate by sector, stage, and decade.

By sectorCount
    By stageCount
      By periodCount

        01 · Deployment strategy vs peers

        Where Euglena deploys vs peers

        Each axis is a Dealroom topic tag — picked from the cluster's most-tagged themes. Values are normalized per axis: the peer with the highest tag-coverage on that axis sits at the edge, others scale relative to them. Toggle between M&A, venture, or both.

        Compare against

        02 · Portfolio market map

        Euglena's portfolio, mapped.

        Each chip is one company. Pill colour shows round type — green for Seed, blue for Series A, purple for B/C+, pink for late-stage, amber for M&A. Bigger sectors keep their full list behind “+ N more”.

        Stage
        Period
        4 of 4 deals

        Market sentiment

        What the market is saying about Euglena

        An AI-synthesized read of the highest-engagement posts about Euglena on X over the past 7 days. We rank by likes & retweets, ignore corporate channels, and surface the themes that broke out from real people.

        Reading the room on X — pulling top posts and synthesizing themes…

        Source: X recent search ranked by engagement (likes + retweets) · Synthesis by Claude · Cached for 1 hour

        See Euglena on the full Dealroom platform

        Live deal flow, founder pedigree, hiring signals, revenue trajectory, and the full cap table.

        Book a demo Explore company profiles